PBH
NYSE · Pharmaceuticals
Prestige Consumer Healthcare
$42.98
-1.34 (-3.02%)
Financial Highlights (FY 2026)
Revenue
1.07B
Net Income
187.20M
Gross Margin
54.7%
Profit Margin
17.5%
Rev Growth
-1.2%
D/E Ratio
0.54
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 54.7% | 54.7% | 54.1% | 54.1% |
| Operating Margin | 28.4% | 25.6% | 32.4% | 26.3% |
| Profit Margin | 17.5% | 16.6% | 30.0% | 31.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.07B | 1.08B | 462.83M | 441.46M |
| Gross Profit | 585.92M | 592.86M | 250.19M | 238.64M |
| Operating Income | 304.37M | 277.17M | 150.18M | 116.02M |
| Net Income | 187.20M | 170.47M | 138.88M | 138.12M |
| Gross Margin | 54.7% | 54.7% | 54.1% | 54.1% |
| Operating Margin | 28.4% | 25.6% | 32.4% | 26.3% |
| Profit Margin | 17.5% | 16.6% | 30.0% | 31.3% |
| Rev Growth | -1.2% | -1.2% | +15.0% | +3.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 360.75M | 360.75M | 1.29B | 1.07B |
| Total Equity | 669.17M | 669.17M | 1.56B | 1.69B |
| D/E Ratio | 0.54 | 0.54 | 0.82 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 324.96M | 312.37M | 217.92M | 202.17M |
| Free Cash Flow | — | — | 109.94M | 68.20M |